by The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 13,873.7 Mn or Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
HER-2 negative breast cancer accounts for around 65-70% of all breast cancer cases. Chemotherapy drugs, hormonal therapy drugs and targeted therapy drugs from key players helps in treatment of HER-2 negative breast cancer. These drugs improves survival rate and quality of life of patients.
Market key trends:
One of the key trends in the HER-2 negative breast cancer market is the rising adoption of targeted therapies. HER-2 negative breast cancer accounts for around 70% of all breast cancer cases, and previouslypatients primarily relied on chemotherapy as the main treatment option. However, with advancements in targeted therapies, regulators have approved several targeted drugs that have shown promising results for HER-2 negative patients. Drugs targeting CDK 4/6 inhibitors and PARP inhibitors have significantly improved survival rates and quality of life for patients. This has boosted the demand for targeted therapies in the market.
SWOT Analysis
Strength: High unmet medical needs as majority of patients do not have targeted therapy options. Previous reliance on chemotherapy has limitations.
Weakness: Limited understanding of disease pathology makes development of targeted drugs challenging. High attrition rates in clinical trials.
Opportunity: Approval and commercialization of ongoing pipeline drugs targeting new pathways can widen treatment landscape. Significant focus on biomarker driven drug development may improve success rates.
Threats: Safety and efficacy concerns of novel targeted agents. Increased regulatory scrutiny for approvals. Patent expiries of blockbuster drugs will increase competition.
Key Takeaways
The Global HER-2 Negative Breast Cancer Market Size is expected to witness high growth at a CAGR of 10.1% over the forecast period of 2023 to 2030, driven by the increasing approval of novel targeted agents.
Regional analysis: North America is expected to dominate the global HER-2 negative breast cancer market over the forecast period owing to growing awareness about disease, availability of advanced healthcare facilities and presence of major market players in the region. However, Asia Pacific region will witness the highest growth rate due to increasing healthcare expenditure, large patient pool and improving healthcare infrastructure in developing countries.
Key players operating in the HER-2 negative breast cancer market include Pfizer Inc., Novartis AG, Merck & Co. Inc., GSK PLC, AstraZeneca, Eli Lilly and Company, and Bristol-Myers Squibb Company (Celgene Corporation), among others. Approval and successful commercialization of ongoing clinical trial drugs by these players will further aid in market growth during the forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
